Ottimo Pharma

Executive Summary

Ottimo Pharma is a clinical-stage biotechnology company focused on developing bifunctional antibodies for oncology, with a lead candidate OTP-01 that simultaneously targets PD-1 and VEGFR2. This dual-paratopic approach aims to enhance anti-tumor activity by combining immune checkpoint inhibition with anti-angiogenic effects, potentially offering improved efficacy over single-target therapies. The company is currently conducting a Phase I/IIa clinical trial for OTP-01, with data readouts expected in the near term. Ottimo's innovative platform addresses key challenges in cancer treatment, and its differentiated mechanism positions it as a promising player in the immuno-oncology space. The company is privately held and based in London, United Kingdom.

Upcoming Catalysts (preview)

• Q4 2026Phase I/IIa interim data readout for OTP-0160% success
• TBDPotential partnership or licensing deal for OTP-0140% success
• Q2 2027IND filing or expansion into additional indications50% success